Clinical use of GLP-1 agonists and DPP4 inhibitors

Research output: Contribution to journalReview ArticleOtherpeer-review

4 Citations (Scopus)

Abstract

Type 2 diabetes is a growing problem, with 387 million people currently affected, and 592 million by 2035. Whilst diet and exercise are the corner stones of treatment, oral hypoglycaemic agents are often needed to achieve glycaemic control, thereby reducing the chance of long term diabetic complications. Biguanides and sulfonylureas have been the standard tablets used for this disorder, until 2005-7 when glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors became available. Their major advantage over sulfonylureas is that they are weight lowering or weight neutral, and have a very low incidence of hypoglycaemia. GLP-1 agonists are injectables, whereas the DPP4 inhibitors are administered orally. Both agents are best used in combination with other hypoglycaemic medication, especially metformin and sodium glucose co-transporter 2 (SGLT2) inhibtors. Usage is increasing, being roughly equal to that of sulfonylureas, but less than that of metformin. Side effects appear to be minimal.

Original languageEnglish
Pages (from-to)8-9
Number of pages2
JournalPancreatology
Volume16
Issue number1
DOIs
Publication statusPublished - 2016

Keywords

  • Dipeptidyl peptidase-4 inhibitors
  • Exocrine pancreatic disease
  • Glucagon-like peptide 1
  • Incretins
  • Oral hypoglycaemics
  • Type 2 diabetes

Cite this

@article{247650c65e7d4b4f94a1f4d1c14afe6c,
title = "Clinical use of GLP-1 agonists and DPP4 inhibitors",
abstract = "Type 2 diabetes is a growing problem, with 387 million people currently affected, and 592 million by 2035. Whilst diet and exercise are the corner stones of treatment, oral hypoglycaemic agents are often needed to achieve glycaemic control, thereby reducing the chance of long term diabetic complications. Biguanides and sulfonylureas have been the standard tablets used for this disorder, until 2005-7 when glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors became available. Their major advantage over sulfonylureas is that they are weight lowering or weight neutral, and have a very low incidence of hypoglycaemia. GLP-1 agonists are injectables, whereas the DPP4 inhibitors are administered orally. Both agents are best used in combination with other hypoglycaemic medication, especially metformin and sodium glucose co-transporter 2 (SGLT2) inhibtors. Usage is increasing, being roughly equal to that of sulfonylureas, but less than that of metformin. Side effects appear to be minimal.",
keywords = "Dipeptidyl peptidase-4 inhibitors, Exocrine pancreatic disease, Glucagon-like peptide 1, Incretins, Oral hypoglycaemics, Type 2 diabetes",
author = "Tuch, {Bernard E.}",
year = "2016",
doi = "10.1016/j.pan.2015.05.465",
language = "English",
volume = "16",
pages = "8--9",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "Elsevier",
number = "1",

}

Clinical use of GLP-1 agonists and DPP4 inhibitors. / Tuch, Bernard E.

In: Pancreatology, Vol. 16, No. 1, 2016, p. 8-9.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Clinical use of GLP-1 agonists and DPP4 inhibitors

AU - Tuch, Bernard E.

PY - 2016

Y1 - 2016

N2 - Type 2 diabetes is a growing problem, with 387 million people currently affected, and 592 million by 2035. Whilst diet and exercise are the corner stones of treatment, oral hypoglycaemic agents are often needed to achieve glycaemic control, thereby reducing the chance of long term diabetic complications. Biguanides and sulfonylureas have been the standard tablets used for this disorder, until 2005-7 when glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors became available. Their major advantage over sulfonylureas is that they are weight lowering or weight neutral, and have a very low incidence of hypoglycaemia. GLP-1 agonists are injectables, whereas the DPP4 inhibitors are administered orally. Both agents are best used in combination with other hypoglycaemic medication, especially metformin and sodium glucose co-transporter 2 (SGLT2) inhibtors. Usage is increasing, being roughly equal to that of sulfonylureas, but less than that of metformin. Side effects appear to be minimal.

AB - Type 2 diabetes is a growing problem, with 387 million people currently affected, and 592 million by 2035. Whilst diet and exercise are the corner stones of treatment, oral hypoglycaemic agents are often needed to achieve glycaemic control, thereby reducing the chance of long term diabetic complications. Biguanides and sulfonylureas have been the standard tablets used for this disorder, until 2005-7 when glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors became available. Their major advantage over sulfonylureas is that they are weight lowering or weight neutral, and have a very low incidence of hypoglycaemia. GLP-1 agonists are injectables, whereas the DPP4 inhibitors are administered orally. Both agents are best used in combination with other hypoglycaemic medication, especially metformin and sodium glucose co-transporter 2 (SGLT2) inhibtors. Usage is increasing, being roughly equal to that of sulfonylureas, but less than that of metformin. Side effects appear to be minimal.

KW - Dipeptidyl peptidase-4 inhibitors

KW - Exocrine pancreatic disease

KW - Glucagon-like peptide 1

KW - Incretins

KW - Oral hypoglycaemics

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84933556052&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2015.05.465

DO - 10.1016/j.pan.2015.05.465

M3 - Review Article

VL - 16

SP - 8

EP - 9

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 1

ER -